Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019)
Ocugen (OCGN) posted Preferred Stock Liabilities of $64347.0 for Q2 2019, down 98.05% on a QoQ basis from $3.3 million in Q4 2018, and down 90.99% year-over-year from $714041.0 in Q2 2018.
Ocugen (OCGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Ocugen's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $64347.0 for Q2 2019.
- Quarterly Preferred Stock Liabilities fell 90.99% year-over-year to $64347.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $64347.0 (down 90.99% YoY) and the FY2018 annual result came in at $3.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $64347.0 for Q2 2019 at Ocugen, down from $3.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $3.3 million in Q4 2018 and bottomed at $64347.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 64,347.00 |
| Dec 31, 2018 | 3.29 Mn |
| Jun 30, 2018 | 714,041.00 |